Understand your options · Spravato

What is Spravato® treatment?

Spravato is a prescription nasal spray containing esketamine. It is an option for adults with treatment-resistant depression, which means depression has not improved enough with usual antidepressant treatments.

You use the spray at a certified healthcare setting, with a care team present. It is not a medicine you take home. For treatment-resistant depression, it may be used on its own or with an oral antidepressant (Janssen Pharmaceuticals, Inc., 2026).

See what treatment involves
Illustrated calm clinic seating area with Transcend branding
A supported setting, with time set aside for treatment and observation. Illustration, not a photograph of a treatment visit.

How could it help depression?

Esketamine acts on a brain chemical system called glutamate. Scientists are still studying exactly how this relieves depression. The goal is to reduce symptoms and help daily life feel more manageable, not to promise a cure.

What does research show?

A randomized study found greater improvement in depression symptoms with esketamine alone than with placebo nasal spray. A separate study found that continuing esketamine with an oral antidepressant reduced relapse among people who had already benefited from treatment (Janik et al., 2025; Daly et al., 2019).

These findings do not mean everyone improves, or that improvement will last without ongoing care. Your team will track your response and decide with you whether treatment should continue.

Plan for support, monitoring, and a ride home.

Spravato can cause sleepiness, dizziness, nausea, and dissociation, a temporary feeling of being disconnected from yourself or your surroundings. Serious risks include slowed breathing, increased blood pressure, and abuse or misuse.

Your team monitors you for at least two hours and until you are safe to leave. Arrange a ride home. Do not drive or operate machinery until the next day after a restful sleep (Janssen Pharmaceuticals, Inc., 2026).

Spravato has not been shown to prevent suicide. It does not replace emergency care or hospitalization when needed. If you are in immediate danger, call 911.

From first conversation to follow-up

What is the treatment journey?

01

Review your history

Discuss symptoms, prior treatments, medicines, health conditions, and goals. Ask about insurance requirements and expected costs.

02

Prepare for a visit

Follow the team’s eating, drinking, and medication instructions. Arrange transportation and allow time for observation.

03

Treat and rest

You use the nasal spray under supervision. Staff check how you feel and monitor your blood pressure and safety before discharge.

04

Review and adjust

Visits are more frequent at first. Your clinician reviews symptoms and side effects, then adjusts the plan based on benefit and tolerability.

Could Spravato fit your care?

An evaluation comes before a treatment decision. Tell the team about vascular disease, bleeding in the brain, pregnancy, allergies, substance use, and all medicines. Some conditions make Spravato unsafe; others require careful review (Janssen Pharmaceuticals, Inc., 2026).

Costs and next steps

Our team can discuss eligibility, visit planning, and insurance review. Coverage and your share of costs depend on your plan and are not guaranteed. Explore our other psychiatric and integrative services or start a conversation.

Discuss Spravato with our team

Research and patient resources

Peer-reviewed study: Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., & Fu, D.-J. (2025). Esketamine monotherapy in adults with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 82(9), 877–887. https://doi.org/10.1001/jamapsychiatry.2025.1317

Relapse-prevention study: Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Thase, M. E., Zajecka, J., Winokur, A., Divacka, I., Fagiolini, A., Cubala, W. J., Bitter, I., Blier, P., Shelton, R. C., … Singh, J. B. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189

Official medicine information: Janssen Pharmaceuticals, Inc. (2026). Spravato (esketamine) nasal spray [Prescribing information]. DailyMed. Read the prescribing information. The FDA label includes a patient Medication Guide with important safety and visit instructions.

This page offers general education, not a diagnosis or personal treatment recommendation. Your clinician can explain benefits and risks for your situation.